Skip to main content
. 2016 Apr 27;36(17):4785–4801. doi: 10.1523/JNEUROSCI.4195-15.2016

Figure 7.

Figure 7.

FGF-1-induced Etd+ uptake in astrocytes in spinal cord slices depends on PLC, intracellular calcium signaling, ATP release, and P2X7R activation. A, Percentage of high Etd+ cells in control or after 1 h FGF-1 (control: 22.0 ± 5.0%; 1 h FGF-1: 50.0 ± 10.0%, n = 7). Percentage of high Etd+ astrocytes was not changed by treatment of control and FGF-1-treated slices with U73343 (1 μm). In contrast, U73122 (1 μm), BAPTA-AM (4 μm), and APY (2 mU/ml) blocked FGF-1-induced uptake, although they did not affect percentage of high Etd+ cells in control conditions (control and FGF-1, respectively: U73343: 19.0 ± 4.0%, 40.5 ± 9.0%; U73122: 16.0 ± 8.3%, 16.0 ± 8.0%, BAPTA-AM: 12.0 ± 8.0%, 10.0 ± 8.0%; APY: 12.0 ± 7.0%, 9.7 ± 6.0%, control and FGF-1, respectively, n = 6). B, The percentage of high Etd+ astrocytes was not changed in control or by FGF-1 in slices treated with 0.1, 1, 10, and 100 μm of A740003 (Control0.1–100 μm: 9.8 ± 2.5%, 9.0 ± 2.3%, 5.0 ± 4.0%, 5.0 ± 2.0%; FGF-10.1–100 μm: 6.0 ± 5.0%, 10.0 ± 2.3%, 5.1 ± 4.0%, 3.0 ± 2.0%, n = 4, B). C, Treatment with BBG at 0.1 to 100 μm did not affect control uptake and blocked FGF-1 induced uptake at 1–100 μm (Control0.1–100 μm: 10.5 ± 8.5%, 14.0 ± 6.0%, 9.0 ± 6.0%, 9.0 ± 5.5%; FGF-10.1–100 μm: 38.0 ± 10.0%, 16.0 ± 7.2%, 10.1 ± 6.0%, 8.0 ± 5.0%, n = 6, C). D, At the same concentrations as for BBG, RB2 did not affect control uptake and significantly reduced uptake at 10 and 100 μm (Control0.1–100 μm: 12.0 ± 9.0%, 10.0 ± 8.5%, 11.0 ± 8.5%, 10.3 ± 8.0%; FGF-10.1–100 μm: 50.8 ± 11.0%, 38.0 ± 11.0%, 29.8 ± 6.0%, 10.0 ± 8.0%). The blockers and apyrase were applied 10–15 min before vehicle or FGF-1 treatment, and left until EtdBr incubation was terminated (1.25 h total period of treatment). n = 5–7. *p < 0.05 versus control. **p < 0.05 versus control. #p < 0.05 versus FGF-1.